MY209803A - Co-crystal forms of a novobiocin analog and proline - Google Patents

Co-crystal forms of a novobiocin analog and proline

Info

Publication number
MY209803A
MY209803A MYPI2020004057A MYPI2020004057A MY209803A MY 209803 A MY209803 A MY 209803A MY PI2020004057 A MYPI2020004057 A MY PI2020004057A MY PI2020004057 A MYPI2020004057 A MY PI2020004057A MY 209803 A MY209803 A MY 209803A
Authority
MY
Malaysia
Prior art keywords
proline
crystal forms
novobiocin analog
novobiocin
analog
Prior art date
Application number
MYPI2020004057A
Other languages
English (en)
Inventor
Xin Jiang
John Allen Walling
Melanie J Bevill
Christopher S Seadeek
Jared P Smit
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of MY209803A publication Critical patent/MY209803A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
MYPI2020004057A 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline MY209803A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Publications (1)

Publication Number Publication Date
MY209803A true MY209803A (en) 2025-08-05

Family

ID=65444361

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020004057A MY209803A (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Country Status (19)

Country Link
US (3) US10717755B2 (enExample)
EP (1) EP3749675B1 (enExample)
JP (3) JP2021512910A (enExample)
KR (2) KR20240155354A (enExample)
CN (2) CN112020506B (enExample)
AR (1) AR114245A1 (enExample)
AU (3) AU2019217821B2 (enExample)
BR (1) BR112020016205A2 (enExample)
CA (2) CA3226385A1 (enExample)
CL (2) CL2020002051A1 (enExample)
CO (1) CO2020009761A2 (enExample)
EA (1) EA202091885A1 (enExample)
IL (2) IL315865A (enExample)
MX (2) MX2020008326A (enExample)
MY (1) MY209803A (enExample)
PE (1) PE20211446A1 (enExample)
SG (1) SG11202007530XA (enExample)
TW (3) TWI868593B (enExample)
WO (1) WO2019156907A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512910A (ja) * 2018-02-07 2021-05-20 リアタ ファーマシューティカルズ インコーポレイテッド ノボビオシン類似体とプロリンとの共結晶形態
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011306391B2 (en) * 2010-09-23 2016-12-15 Nuformix Limited Aprepitant L-proline composition and cocrystal
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CN104159584A (zh) * 2011-11-25 2014-11-19 诺弗米克斯有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
NZ629778A (en) * 2012-02-09 2016-03-31 Univ Kansas C-terminal hsp90 inhibitors
US9556216B2 (en) * 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
CN106536498A (zh) 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
PL3202772T3 (pl) 2014-09-30 2021-02-22 Jiangsu Hengrui Medicine Co. Ltd. Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2
JP2021512910A (ja) 2018-02-07 2021-05-20 リアタ ファーマシューティカルズ インコーポレイテッド ノボビオシン類似体とプロリンとの共結晶形態

Also Published As

Publication number Publication date
IL276583B1 (en) 2024-11-01
SG11202007530XA (en) 2020-09-29
KR20240155354A (ko) 2024-10-28
AU2019217821A1 (en) 2020-09-24
TWI868593B (zh) 2025-01-01
PE20211446A1 (es) 2021-08-05
CN112020506B (zh) 2024-10-11
TWI797249B (zh) 2023-04-01
EA202091885A1 (ru) 2021-01-15
US11401294B2 (en) 2022-08-02
CL2022003784A1 (es) 2023-06-09
MX2020008326A (es) 2020-09-28
CN118894894A (zh) 2024-11-05
AR114245A1 (es) 2020-08-12
JP2026012851A (ja) 2026-01-27
CO2020009761A2 (es) 2020-10-30
TW202510893A (zh) 2025-03-16
NZ767558A (en) 2024-11-29
US20190241599A1 (en) 2019-08-08
IL276583A (en) 2020-09-30
US20200347088A1 (en) 2020-11-05
MX2022012856A (es) 2022-11-30
TW201945381A (zh) 2019-12-01
AU2024227646A1 (en) 2024-11-14
CA3090646A1 (en) 2019-08-15
EP3749675B1 (en) 2025-12-31
CA3090646C (en) 2024-02-27
US20240043465A1 (en) 2024-02-08
AU2022283638A1 (en) 2023-02-02
CL2020002051A1 (es) 2021-02-19
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
CA3226385A1 (en) 2019-08-15
EP3749675A1 (en) 2020-12-16
WO2019156907A1 (en) 2019-08-15
JP2024001167A (ja) 2024-01-09
AU2022283638B2 (en) 2024-07-25
IL315865A (en) 2024-11-01
US10717755B2 (en) 2020-07-21
TWI915111B (zh) 2026-02-11
BR112020016205A2 (pt) 2020-12-15
AU2019217821B2 (en) 2022-09-08
IL276583B2 (en) 2025-03-01
JP2021512910A (ja) 2021-05-20
CN112020506A (zh) 2020-12-01
KR102718111B1 (ko) 2024-10-17

Similar Documents

Publication Publication Date Title
NZ629778A (en) C-terminal hsp90 inhibitors
CL2022003784A1 (es) Formas co-cristalinas de un análogo de novobiocina y prolina
GEP20257823B (en) Amino quinazoline derivatives as p2x3 inhibitors
MY146662A (en) Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
WO2014100071A3 (en) Substituted pyrrolopyrimidines as hdm2 inhibitors
CR9485A (es) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
ATE528005T1 (de) 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
CL2007002288A1 (es) Compuestos derivados de imidazol-amina condensados, inhibidores de la beta-secretasa; proceso de preparacion; composicion farmaceutica, util para el tratamiento, prevencion o mejoramiento de enfermedades tales como enfermedad de alzheimer, deterioro
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MY161607A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
MX2010003948A (es) N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
EA200800081A1 (ru) Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты)
WO2023278325A8 (en) Bifunctional compounds that degrade alk and uses thereof
EP4663190A3 (en) Muscarinic receptor agonists
TN2009000018A1 (fr) Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
MX2024002411A (es) Antagonista biológico que contiene anillos aromáticos, y método para su preparación y su uso.
EP4233871A3 (en) Inhibiting the transient receptor potential a1 ion channel
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
NZ590276A (en) Use of nifurtimox for treating giardiasis